Micafungin Olikla

Micafungin, the active ingredient in Micafungin Olikla, is an echinocandin presented as an intravenous solution for intravenous use. It treats invasive Candida infections and is used for prophylaxis in high‑risk patients such as those undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal used to manage serious Candida infections and to prevent infection in high‑risk patients. - Invasive candidiasis: clears bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves fungal infection of the esophagus. - Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation: prevents invasive disease. - Candida peritonitis and intra‑abdominal infections: treats these severe intra‑abdominal fungal infections.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Headache: occasional mild headache. - Infusion‑related reactions: flushing, chills, or erythema. - Elevated liver enzymes: mild transaminase increase. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Hepatic failure: significant liver dysfunction. - Severe hypersensitivity: anaphylactic reactions. - Stevens‑Johnson syndrome: severe skin and mucosal involvement. - Renal failure: impaired kidney function. - Severe neutropenia: marked reduction in neutrophil count. - Cardiovascular collapse: rare hypotensive events.

When using Micafungin, clinicians should consider several safety measures. - Renal impairment: adjust therapy and monitor kidney function. - Hepatic impairment: assess liver enzymes before and during treatment. - Concomitant hepatotoxic drugs: avoid or monitor for additive liver injury. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Pediatric use: not approved; use only if clearly justified. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Azole antifungals: increased risk of hepatotoxicity when combined. - Rifampin: may reduce micafungin plasma concentrations, lowering efficacy. - Cyclosporine: potential for elevated cyclosporine levels and toxicity.

Moderate Interactions (Monitor Closely): - Statins: heightened risk of myopathy or rhabdomyolysis. - Warfarin: possible alteration of INR, requiring closer monitoring. - Hormonal contraceptives: may reduce contraceptive effectiveness.